Literature DB >> 23431097

Albuminuria associates with calcified atherosclerotic plaque in African Americans with diabetes.

Jasmin Divers, Lynne E Wagenknecht, Donald W Bowden, J Jeffrey Carr, R Caresse Hightower, S Carrie Smith, Jianzhao Xu, Carl D Langefeld, Barry I Freedman.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 23431097      PMCID: PMC3579330          DOI: 10.2337/dc12-1589

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


× No keyword cloud information.
Relative to individuals with European ancestry, presence and severity of calcified atherosclerotic plaque (CP) are markedly lower in individuals with African ancestry (1,2). Factors potentially contributing to the ethnic variation in susceptibility to atherosclerosis include different relationships between CP and serum 25 hydroxyvitamin D concentrations and pericardial adipose tissue volumes in African Americans (AAs) relative to European Americans (EAs) (3,4). In addition, significant positive associations have been observed between CP and albuminuria in EAs with type 2 diabetes (5) but not AAs (419 subjects from 297 African American Diabetes Heart Study [AA-DHS] families) (6). Therefore, it remains unclear whether ethnic differences exist in the effect of albuminuria on risk for development and progression of CP. To improve power for detecting associations between albuminuria and CP in AAs, we retested relationships between urine albumin:creatinine ratio (UACR) and CP in the full AA-DHS sample containing 597 unrelated participants. Generalized linear models were fitted to test for associations between UACR and CP in the coronary arteries, carotid arteries, and infrarenal aorta. The effect sizes for the UACR versus CP associations in the new analysis are shown in Table 1 and did not change markedly from our initial report (6). Significant positive associations were now observed in all three vascular beds adjusting for age, sex, BMI, and estimated glomerular filtration rate. In a full model that adjusted for age, sex, BMI, diastolic blood pressure, and systolic blood pressure, use of ACE inhibitors and angiotensin receptor blockers, LDL cholesterol, HDL cholesterol, HbA1c, and smoking in 491 unrelated individuals, the effect remained significant for coronary and aorta CP but not carotid CP; carotid vascular beds typically have lower CP scores than coronary arteries and aorta.
Table 1

Relationships between albuminuria and calcified atherosclerotic plaque

Relationships between albuminuria and calcified atherosclerotic plaque The difference in significance between the albuminuria and CP relationship in these analyses and our initial report (6) appears to be the result of an increased sample size. After adjustment, the initial analyses included only 283 samples with some related individuals. The current analysis used data from nearly twice as many subjects. In addition, differences between the final numbers of samples in both analyses are due to missing data; SAS excludes samples if missing data exists for one covariate in the model. We now conclude that albuminuria is positively associated with CP in the large vessels of individuals with type 2 diabetes of African and European ancestry. Observed ethnic differences in susceptibility to CP appear more likely to relate to nonconventional cardiovascular disease risk factors and gene polymorphisms with different distributions across population groups, not the effects of albuminuria (7).
  7 in total

1.  Ethnic differences in the relationship between pericardial adipose tissue and coronary artery calcified plaque: African-American-diabetes heart study.

Authors:  Jasmin Divers; Lynne E Wagenknecht; Donald W Bowden; J Jeffrey Carr; R Caresse Hightower; Thomas C Register; Jianzhao Xu; Carl D Langefeld; Barry I Freedman
Journal:  J Clin Endocrinol Metab       Date:  2010-09-01       Impact factor: 5.958

2.  Racial differences in coronary artery calcification in older adults.

Authors:  Anne B Newman; Barbara L Naydeck; Jeff Whittle; Kim Sutton-Tyrrell; Daniel Edmundowicz; Lewis H Kuller
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-03-01       Impact factor: 8.311

Review 3.  Effect of race and genetics on vitamin D metabolism, bone and vascular health.

Authors:  Barry I Freedman; Thomas C Register
Journal:  Nat Rev Nephrol       Date:  2012-06-12       Impact factor: 28.314

4.  The impact of ethnicity and sex on subclinical cardiovascular disease: the Diabetes Heart Study.

Authors:  B I Freedman; F C Hsu; C D Langefeld; S S Rich; D M Herrington; J J Carr; J Xu; D W Bowden; L E Wagenknecht
Journal:  Diabetologia       Date:  2005-11-01       Impact factor: 10.122

5.  Relationship between albuminuria and cardiovascular disease in Type 2 diabetes.

Authors:  Barry I Freedman; Carl D Langefeld; Kurt K Lohman; Donald W Bowden; J Jeffrey Carr; Stephen S Rich; Lynne E Wagenknecht
Journal:  J Am Soc Nephrol       Date:  2005-05-04       Impact factor: 10.121

6.  Vitamin d, adiposity, and calcified atherosclerotic plaque in african-americans.

Authors:  Barry I Freedman; Lynne E Wagenknecht; Kristen G Hairston; Donald W Bowden; J Jeffrey Carr; R Caresse Hightower; Ethel J Gordon; Jianzhao Xu; Carl D Langefeld; Jasmin Divers
Journal:  J Clin Endocrinol Metab       Date:  2010-01-08       Impact factor: 5.958

7.  Ethnic differences in the relationship between albuminuria and calcified atherosclerotic plaque: the African American-diabetes heart study.

Authors:  Jasmin Divers; Lynne E Wagenknecht; Donald W Bowden; J Jeffrey Carr; R Caresse Hightower; Jianzhao Xu; Carl D Langefeld; Barry I Freedman
Journal:  Diabetes Care       Date:  2009-10-13       Impact factor: 19.112

  7 in total
  1 in total

1.  Vitamin D Associations With Renal, Bone, and Cardiovascular Phenotypes: African American-Diabetes Heart Study.

Authors:  Barry I Freedman; Jasmin Divers; Gregory B Russell; Nicholette D Palmer; Lynne E Wagenknecht; S Carrie Smith; Jianzhao Xu; J Jeffrey Carr; Donald W Bowden; Thomas C Register
Journal:  J Clin Endocrinol Metab       Date:  2015-07-21       Impact factor: 5.958

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.